Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma.
A 66-year old female with HIV-negative classic Kaposi's sarcoma responded to mTOR targeting by rapamycin. The response was well documented by PET-CT. This case provides supporting evidence that the mTOR pathway may be important in the tumorigenesis of KS and that rapamycin may have activity in this disease.
Unit of Bone and Soft Tissue Oncology, Division of Oncology, Tel-Aviv Sourasky Medical Center, 6 Weitzman Street, Tel-Aviv 64239, Israel.
Ofer
O
Merimsky
Irina
I
Jiveliouk
Ronit
R
Sagi-Eisenberg